Pharmacokinetic and pharmacodynamic correlations of cyclosporine therapy in stable renal transplant patients: Evaluation of long-term target C2

International Immunopharmacology

Volumn 3, Issue 7, 2003, Pages 987-999

  Brunet, M ^a   Campistol, J M ^a   Millan O ^a   Vidal, E ^a   Esforzado, N ^a   Rojo, I ^a   Jimenez O ^a   Oppenheimer, F ^a   Corbella, J ^a   Martorell, J ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Calcineurin activity; Cyclosporine; Efficacy; IFN ; IL 2; Pharmacodynamics; Pharmacokinetics; Toxicity

Indexed keywords

CALCINEURIN; CYCLOSPORIN; GAMMA INTERFERON; INTERLEUKIN 2;

ADULT; AREA UNDER THE CURVE; ARTICLE; CHRONIC GLOMERULONEPHRITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; CYTOKINE PRODUCTION; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; ENZYME ACTIVITY; ENZYME SYNTHESIS; FEMALE; GRAFT REJECTION; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; INTERSTITIAL NEPHRITIS; KIDNEY DISEASE; KIDNEY POLYCYSTIC DISEASE; KIDNEY TRANSPLANTATION; MALE; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; SURGICAL PATIENT;

EID: 10744219578     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1567-5769(03)00097-3     Document Type: Article

References (21)

1. Allison A.C. Immunosuppressive drugs: the first 50 years and a glance forward. Immunopharmacology. 47:2000;63-83.
2. Halloran P.F., Melk A. Tailoring therapy: balancing toxicity and chronic allograft dysfunction. Transplantation Proceedings. 33(Suppl. 3A):2001;7S-10S.
3. Campistol J.M., Grinyo J.M. Exploring treatment options in renal transplantation: the problems of chronic allograft dysfunction and drug-related nephrotoxicity. Transplantation. 71:2001;SS42-SS51.
4. Wong S.H.Y. Therapeutic drug monitoring for immunosuppressants. Clinica Chimica Acta. 313:2001;241-253.
5. Lindholm A., Kahan B.D. Influence of cyclosporine pharmacokinetics, trough concentrations, and AUC monitoring on outcome after kidney transplantation. Clinical Trials and Therapeutics. 54:1993;205-218.
6. Johnston A., David O.J., Cooney G.F. Pharmacokinetic validation of Neoral absorption profiling. Elsevier. 2000;53S-56S.
7. 1 formulation. Biodrugs. 15(5):2001;279-290.
8. Belitsky P., Levy G.A., Johnston A. Neoral absorption profiling: an evolution in effectiveness. Transplantation Proceedings. 32(Suppl. 3A):2000;45S-52S.
9. 2 monitoring: a review. Transplantation. 73:2002;S3-S11.
10. 2 monitoring: an international consensus statement. Transplantation. 73:2002;S12-S18.
11. Dambrin C., Klupp J., Morris R.E. Pharmacodynamics of immunosuppressive drugs. Current Opinion in Immunology. 12:2000;557-562.
12. Beresini M.H., Davalian D., Alexander S., Toton-Quinn R., Barnett B., Cerelli M.J.et al. Evaluation of EMIT® cyclosporine assay for use with whole blood. Clinical Chemistry. 39(11):1993;2235-2241.
13. Fruman D.A., Pai S.Y., Klee C.B., Burakoff S.J., Bierer B.E. Measurement of calcineurin phosphate activity in cell extracts. Methods. 9:1996;146-154.
14. Stein C.M., Murray J.J., Wood A.J.J. Inhibition of stimulated interleukin-2 production in whole blood: a practical measure of cyclosporine effect. Clinical Chemistry. 45(9):1999;1477-1484.
15. Halloran P.F., Kung L., Noujaim J. Calcineurin and the biological effect of cyclosporine and tacrolimus. Transplantation Proceedings. 30:1998;2167-2170.
16. Oellerich M., Armstrong V.W. Two-hour cyclosporine concentration determination: appropriate tool to monitor neoral therapy. Therapeutic Drug Monitoring. 24(1):2002;40-46.
17. Quien R.M., Kaiser B.A., Dunn S.P., Kulinsky A., Polinsky M., Baluarte H.J.et al. Calcinerin activity in children with renal transplants receiving cyclosporine. Transplantation. 64(10):1997;1486-1489.
18. Catarovich M., Barkun J.S., Tchervenkov J.I., Besner J.G., Aspeslet L., Metrakos P. Comparison of neural dose monitoring with cyclosporine through levels versus 2-hr postdose levels in stable liver transplant patients. Transplantation. 66(12):1998;1621-1627.
19. Batiuk T.D., Pazderka F., Enns J., De Castro L., Halloran P.F. Cyclosporine inhibition of calcineurin activity in human leukocytes in vivo is rapidly reversible. Journal of Clinical Investigation. 96:1995;1254-1260.
20. Halloran P.F., Helms L.M.H., Kung L., Noujaim J. The temporal profile of carcineurin inhibition by cyclosporine in vivo. Transplantation. 68:1999;1356-1361.
21. Kung L., Halloran P.F. Immunophilins may limit calcineurin inhibition by cyclosporine and tacrolimus at high drug concentrations. Transplantation. 70:2000;327-335.